Pegilated interferon alpha 2b «Pegaltevir» chronic hepatitis C treatment (randomized clinical trial)

Pegilated interferon alpha 2b «Pegaltevir» chronic hepatitis C treatment (randomized clinical trial)

Bibliographic Details
Main Authors:	Marina V. Mayevskaya, Ye. N. Bessonova, P. O. Bogomolov, N. I. Geyvandova, K. V. Zhdanov, V. G. Morozov, V. D. Pasechnikov, I. Yu. Khomenko, A. V. Yagoda, V. T. Ivashkin
Format:	Article
Language:	Russian
Published:	Gastro LLC 2018-08-01
Series:	Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:	хронический гепатит с лечение исследуемый препарат пегальтевир® препарат сравнения пегинтрон® эффективность безопасность
Online Access:	https://www.gastro-j.ru/jour/article/view/97

Similar Items

Efficacy and safety of the Russian protease inhibitor narlaprevir at treatment-naive and earlier treated noncirrhotic patients with the 1st genotype chronic hepatitis C (PIONEER study)
by: M. V. Mayevskaya, et al.
Published: (2018-08-01)

THE PROBLEMS ASSOCIATED WITH SWITCHING BRAND-NAME ANTIEPILEPTIC DRUGS TO GENERICS: A FOCUS ON TOPAMAX: A REVIEW OF LITERATURE AND A CASE REPORT
by: K. Yu. Mukhin, et al.
Published: (2016-08-01)

ВИКОРИСТАННЯ КОМБІНОВАНОГО ГЕПАТОПРОТЕКТОРА “ЛЕСФАЛЬ ВІТ” ДЛЯ КОМПЛЕКСНОГО ЛІКУВАННЯ ТА ПРОФІЛАКТИКИ ТОКСИЧНОГО ГЕПАТИТУ В ПАЦІЄНТІВ ІЗ ЛІМФОПРОЛІФЕРАТИВНИМИ ЗАХВОРЮВАННЯМИ
by: O. Ye. Samogalska, et al.
Published: (2019-01-01)

Chronic catarrhal gingivitis treatment in the orthodontic patients
by: T F Kosyreva, et al.
Published: (2009-12-01)

Flow Dispersion for Obtaining Ivermectin Encapsulated in Polycaprolactone Microparticles
by: O. I. Rybchenko, et al.
Published: (2022-05-01)

The role of pharmacist in early phase clinical research
by: A. V. Vozzhaev, et al.
Published: (2018-05-01)

Signicef® (levoflaxacin 0.5%) eye drops in clinical practice
by: E. A. Spiridonov
Published: (2014-07-01)

Środki wspomagające w treningu siłowym
by: Konrad Kraszewski
Published: (2016-12-01)

THE MULTIFUNCTIONAL ACTIVITY OF THE PREPARATION OF CHITOSAN – ARTAFIDIN
by: Lubov Demianovna Shamanskaya, et al.
Published: (2016-10-01)

Comparative clinical and economic evaluation of two alternative antiviral therapy regimens for influenza patients
by: I. I. Tokin, et al.
Published: (2018-07-01)

Combined modality therapy for exsudative form of age-related macular degeneration
by: М. V. Budzinskaya, et al.
Published: (2013-03-01)

Combined modality therapy for exsudative form of age-related macular degeneration
by: М. V. Budzinskaya, et al.
Published: (2013-01-01)

MAJOR PRINCIPLES OF EPILEPSY TREATMENT. ALGORITHM OF SELECTION OF ANTIEPILEPTIC DRUGS
by: K. Yu. Mukhin, et al.
Published: (2015-04-01)

UP TO DATE ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS AND REAL CLINICAL PRACTICE
by: S. Yu. Martsevich, et al.
Published: (2015-12-01)

Bisoprolol medications in a comparative study on effectiveness and tolerability of original agent and its generic in patients with mild to moderate arterial hypertension
by: S. Yu. Martsevich, et al.
Published: (2007-12-01)

THE KARDIOKANON STUDY: A WAY TO SETTLE THE SUBJECT OF CLINICAL EQUIVALENCE OF GENERIC AND ORIGINAL DRUGS
by: S. Yu. Martsevich, et al.
Published: (2015-12-01)

ACHIEVEMENT OF TARGET BLOOD PRESSURE LEVEL IN HYPERTENSIVE PATIENTS WITH AMLODIDINE: ORIGINAL DRUG VERSUS GENERIC
by: S. Yu. Martsevich, et al.
Published: (2016-01-01)

DEMAND ON ADSORPTIVE INTESTINAL PREPARATIONS ANALYSIS USING A VYSHKOVSKY'S INDEX
by: A. V. Bondarev, et al.
Published: (2015-09-01)

Выбор препарата для лекарственной терапии с учетом особенностей субстанции
by: С. С. Вялов, et al.
Published: (2012-08-01)

THE RESULTS OF THE EFFICACY AND SAFETY OF THE NEW RUSSIAN DRUG 6НР IN THE ANTIRETROVIRAL THERAPY REGIMENS OF HIV-INFECTED PATIENTS
by: A. V. Kravchenko, et al.
Published: (2019-03-01)

EVALUATION OF EFFICIENCY AND SAFETY OF CHEMOTHERAPY FOR PROSTATE TUBERCULOSIS PATIENTS
by: E. V. Kulchavenya, et al.
Published: (2015-09-01)

THERAPEUTIC EQUIVALENCE OF ORIGINAL CLOPIDOGREL (PLAVIX) AND ITS GENERIC (EGITROMB). RESULTS OF COMPARATIVE RANDOMIZED CROSS-OVER BLIND STUDY
by: V. V. Yakusevich, et al.
Published: (2016-01-01)

The modern options of chronic hepatitis C antiviral therapy with daclatasvir: results of named patient program
by: V. T. Ivashkin, et al.
Published: (2018-08-01)

ASSESSMENT OF THERAPEUTICAL EQUIVALENCY OF ORIGINAL AND GENERIC INDAPAMIDE IN HYPERTENSIVE PATIENTS BY RANDOMIZED CROSS-OVER STUDY
by: N. P. Kutishenko, et al.
Published: (2015-12-01)

STATIN GENERICS: EFFICACY AND SAFETY RATIO
by: V. P. Voronina, et al.
Published: (2016-01-01)

PHARMACEUTICAL DEVELOPMENT OF DRUGS FOR PEDIATRIC PRACTICE: FUNDAMENTAL BASES AND SPECIFIC FEATURES
by: I. A. Narkevich, et al.
Published: (2019-01-01)

THE PROBLEM OF MEDICINES INTERCHANGEABILITY. FOCUS ON PERINDOPRIL
by: A. I. Malyhina, et al.
Published: (2015-09-01)

КЛИНИЧЕСКИЙ СЛУЧАЙ ТЕРАПИИ БУЛЕВИРТИДОМ ХРОНИЧЕСКОЙ HDV-ИНФЕКЦИИ
by: Н. А. Илларионова, et al.
Published: (2023-06-01)

Hypotensive effect of bi-potassium salt of 1-hexadecyl-2-methylcarbamoylphosphatidic acid in rats with renovascular hypertension
by: N. Y. Khromova, et al.
Published: (2018-12-01)

CLINICAL EFFICACY OF HERBAL DRUG WITH ANTI-INFLAMMATORY AND IMMUNOSTIMULATING ACTIVITY IN CHILDREN WITH ADENOIDITIS
by: I. I. Klimova, et al.
Published: (2013-09-01)

ETIOTROPIC THERAPY OF VIRAL HEPATITIS
by: S. B. Chuelov, et al.
Published: (2017-09-01)

DOMESTIC SPECTRUM OF ANTIVIRAL DRUG — UMIFENOVIR AS ETIOTROPIC THERAPY OF INFLUENZA
by: L. V. Osidak, et al.
Published: (2016-09-01)

THE CHOICE OF THE DRUG AMLODIPINE FOR THE HYPERTENSION TREATMENT FROM THE STANDPOINT OF ECONOMIC FEASIBILITY
by: S. Yu. Martsevich, et al.
Published: (2016-01-01)

Experience of using bedaquiline in the treatment of pulmonary tuberculosis patients with multiple drug resistance
by: T. I. Morozova, et al.
Published: (2016-02-01)

ACETYLSALICYLIC ACID IN LOW DOSES FOR SECONDARY PREVENTION OF CARDIO-VASCULAR COMPLICATIONS
by: N. A. Dmitrieva, et al.
Published: (2016-01-01)

Упрочняющие добавки для формованного древесного топлива
by: Макеенко А. А., et al.
Published: (2018-01-01)

Efficacy and safety of triple therapy with recombinant interleukin-1β, recombinant interferon-α and ribavirin in patients with chronic hepatitis C, genotype 1 infection, the non-responders to previous treatment with interferon and ribavirin
by: Yu. V. Lobzin, et al.
Published: (2014-09-01)

Сost-effectiveness of the second wave of protease inhibitors in the treatment of chronic hepatitis C (genotype 1) in patients not previously treated with antiviral drugs, and for relapsed disease
by: A. V. Rudakova, et al.
Published: (2016-04-01)

Cost-effectiveness of narlaprevir in the chronic hepatitis C (genotype 1) therapy in treatment-naïve patients and relapsers
by: D. A. Gusev, et al.
Published: (2016-11-01)

Two-stage prevention of purulent-septic complications after surgery in patients with pararectal fistulas
by: O. E. Lisin, et al.
Published: (2021-11-01)